NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $11.26 -0.28 (-2.43 %) (As of 12/13/2018 04:00 PM ET)Previous Close$11.54Today's Range$11.26 - $11.6152-Week Range$11.02 - $21.20Volume203,109 shsAverage Volume1.22 million shsMarket Capitalization$1.87 billionP/E Ratio-12.20Dividend YieldN/ABeta1.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts. Receive IRWD News and Ratings via Email Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IRWD Previous Symbol CUSIP46333X10 Webwww.ironwoodpharma.com Phone617-621-7722 Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.21 Price-To-Earnings Trailing P/E Ratio-12.20 Forward P/E Ratio-12.37 P/E GrowthN/A Sales & Book Value Annual Sales$298.28 million Price / Sales5.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book160.86 Profitability EPS (Most Recent Fiscal Year)($0.93) Net Income$-116,930,000.00 Net Margins-82.15% Return on EquityN/A Return on Assets-29.59% Miscellaneous Employees730 Outstanding Shares154,060,000Market Cap$1.87 billion OptionableOptionable Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions What is Ironwood Pharmaceuticals' stock symbol? Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD." How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.24. The biotechnology company had revenue of $68.69 million for the quarter, compared to analyst estimates of $93.48 million. The firm's quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.18) earnings per share. View Ironwood Pharmaceuticals' Earnings History. When is Ironwood Pharmaceuticals' next earnings date? Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Ironwood Pharmaceuticals. What price target have analysts set for IRWD? 12 brokerages have issued 1-year price targets for Ironwood Pharmaceuticals' stock. Their forecasts range from $11.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $16.35 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals. What is the consensus analysts' recommendation for Ironwood Pharmaceuticals? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 4 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals. Has Ironwood Pharmaceuticals been receiving favorable news coverage? Media coverage about IRWD stock has trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Are investors shorting Ironwood Pharmaceuticals? Ironwood Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 12,334,900 shares, a decrease of 19.6% from the October 31st total of 15,340,547 shares. Based on an average daily volume of 1,983,105 shares, the days-to-cover ratio is presently 6.2 days. Currently, 9.0% of the shares of the stock are sold short. View Ironwood Pharmaceuticals' Current Options Chain. Who are some of Ironwood Pharmaceuticals' key competitors? Some companies that are related to Ironwood Pharmaceuticals include Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Alkermes (ALKS), Amarin (AMRN), Catalent (CTLT), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), Loxo Oncology (LOXO), TESARO (TSRO), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH) and Taro Pharmaceutical Industries (TARO). Who are Ironwood Pharmaceuticals' key executives? Ironwood Pharmaceuticals' management team includes the folowing people: Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 54)Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 45)Dr. Mark G. Currie, Sr. VP, Chief Scientific Officer and Pres of R&D (Age 63)Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 48)Mr. Thomas A. McCourt, Sr. VP of Marketing & Sales and Chief Commercial Officer (Age 61) Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.00%), Vanguard Group Inc (8.00%), Janus Henderson Group PLC (5.21%), Loomis Sayles & Co. L P (0.99%), Pictet Asset Management Ltd. (0.67%) and Bank of New York Mellon Corp (0.41%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals. Which major investors are selling Ironwood Pharmaceuticals stock? IRWD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Pictet Asset Management Ltd., United Services Automobile Association, Artal Group S.A., Janus Henderson Group PLC, Broderick Brian C, Trexquant Investment LP and Mizuho Securities USA LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals. Which major investors are buying Ironwood Pharmaceuticals stock? IRWD stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Fosun International Ltd, Man Group plc, First Trust Advisors LP, Federated Investors Inc. PA, Trustcore Financial Services LLC and PNC Financial Services Group Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ironwood Pharmaceuticals' stock price today? One share of IRWD stock can currently be purchased for approximately $11.26. How big of a company is Ironwood Pharmaceuticals? Ironwood Pharmaceuticals has a market capitalization of $1.87 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe. What is Ironwood Pharmaceuticals' official website? The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com. How can I contact Ironwood Pharmaceuticals? Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected] MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 381 (Vote Outperform)Underperform Votes: 461 (Vote Underperform)Total Votes: 842MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2018 by MarketBeat.com StaffFeatured Article: What is Net Asset Value (NAV)?